Aim immunotech announces first dose level is generally well-tolerated in phase 1b/2 study of ampligen and imfinzi as a combination therapy for late-stage pancreatic cancer

Ocala, fla., april 29, 2024 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”) today announced that it has taken an essential step forward in testing the combination of aim's ampligen® (rintatolimod) and astrazeneca's anti-pd-l1 immune checkpoint inhibitor imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer (the “duripanc” study).
AIM Ratings Summary
AIM Quant Ranking